Detection method of VIM type carbapenemase drug-resistant gene
Through enzymatic recombinant isothermal amplification technology, the rapid detection of VIM genes at room temperature has been solved, and the problems of complex operation, time-consuming and limited application in the existing technology have been solved, and high sensitivity and specific VIM gene detection is achieved, suitable for on-site and Clinical application.
Patent Information
- Application Number
- CN202411503542.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-25
- Publication Date
- 2024-12-06
AI Technical Summary
The methods used in the detection of VIM genes in the prior art are complex in operation, time-consuming, high cost, and limited in application in room temperature detection. In particular, isothermal amplification technology such as LAMP technology, with complex primer design and long reaction temperature and time. question.
Using enzymatic recombinant isothermal amplification technology (ERA), using specific primer pairs and fluorescent probes, the VIM gene was quickly detected at room temperature through constant temperature amplification technology. The reaction temperature was 36℃~42℃ and the reaction time was 15-60 In minutes, combined with fluorescence signal detection, a detection method with simple operation, short time consuming and high sensitivity is provided.
It realizes rapid, sensitive and highly specific VIM gene detection at room temperature, with a sensitivity of 0.01ng/μL and has no cross-reaction with other carbapenemase subtype genes, which is suitable for on-site detection and clinical applications.
Smart Images

Figure BDA0005103196270000071 
Figure BDA0005103196270000081 
Figure BDA0005103196270000101
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biotechnology, and in particular, relates to a method for detecting VIM genes based on ERA technology. Background Art
[0002] Bacterial resistance has become a major challenge in the field of global public health, among which carbapenem-resistant Enterobacteriaceae (CRE) are the most serious forms of infection. CRE are Enterobacteriaceae that are not sensitive to doripenem, ertapenem, meropenem or imipenem, or are confirmed to produce carbapenemases, and are important clinical pathogens. CRE has attracted much attention due to its high drug resistance, rapid transmission speed and high mortality rate.
[0003] VIM is a common metallo-β-lactamase with strong carbapenem hydrolysis activity in clinical practice. Due to the presence of gene elements that mediate transfer in its resistance gene, it is easy to transfer between different bacteria, resulting in the widespread spread of carbapenem resistance. Therefore, the fastest and most effective way to monitor this type of VIM enzyme-producing strain is to detect its resistance gene.
[0004] At present, the main technology used to detect VIM genes is molecular biological detection. According to the amplification temperature, it can be divided into variable temperature amplification technology and isothermal amplification detection technology, including polymerase chain reaction (PCR), fluorescent quantitative PCR, loop-mediated isothermal amplification PCR (LAMP), etc. Variable temperature amplification PCR requires a relatively expensive thermal cycler, which is complex and time-consuming to operate. As a common isothermal amplification technology, LAMP technology still has certain shortcomings and deficiencies, such as complex primer design, reaction temperature of about 60°C and long reaction time, which limits its application in on-site detection.
[0005] Therefore, there is an urgent need to develop a detection method for the VIM gene that is simple to operate, time-saving, highly sensitive, and specific and suitable for on-site detection at room temperature. Summary of the invention
[0006] The object of the present invention is to provide a method for detecting VIM gene which is simple to operate, short in time, high in sensitivity, strong in specificity and suitable for on-site detection at room temperature.
[0007] In a first aspect of the present invention, a non-diagnostic and non-therapeutic VIM gene amplification method is provided, the amplification method comprising the steps of: performing amplification in a reaction system, the reaction system containing a specific primer pair for amplifying the VIM gene, the primer pair comprising: a sequence as shown in SEQ ID NO: 7, and a sequence as shown in SEQ ID NO: 9.
[0008] In another preferred embodiment, the minimum detection concentration of VIM in the method is 0.005-0.015 ng / μL.
[0009] In another preferred embodiment, the minimum detection concentration of VIM in the method is 0.01 ng / μL.
[0010] In another preferred embodiment, the reaction system further comprises a probe, and the probe comprises a sequence as shown in SEQ ID NO:1 or SEQ ID NO:11.
[0011] In another preferred embodiment, the probe is labeled with a fluorescent group and a quencher group.
[0012] In another preferred embodiment, the 5' end of the probe is labeled with a fluorescent gene FAM, and the 3' end is labeled with a quenching group BHQ.
[0013] In another preferred example, the primer pair includes a sequence as shown in SEQ ID NO: 8 or its complementary chain, and a sequence as shown in SEQ ID NO: 9 or its complementary chain.
[0014] In another preferred example, the primer pair includes a sequence as shown in SEQ ID NO: 3 or its complementary chain, and a sequence as shown in SEQ ID NO: 10 or its complementary chain.
[0015] In another preferred example, the primer pair includes a sequence as shown in SEQ ID NO: 7 or its complementary chain, and a sequence as shown in SEQ ID NO: 10 or its complementary chain.
[0016] In another preferred example, the primer pair includes a sequence as shown in SEQ ID NO: 8 or its complementary chain, and a sequence as shown in SEQ ID NO: 10 or its complementary chain.
[0017] In another preferred example, the primer pair includes a sequence as shown in SEQ ID NO: 12 or a complementary chain thereof, and a sequence as shown in SEQ ID NO: 19 or a complementary chain thereof.
[0018] In another preferred example, the primer pair includes a sequence as shown in SEQ ID NO: 14 or its complementary chain, and a sequence as shown in SEQ ID NO: 19 or its complementary chain.
[0019] In another preferred example, the primer pair includes a sequence as shown in SEQ ID NO: 6 or its complementary chain, and a sequence as shown in SEQ ID NO: 9 or its complementary chain.
[0020] In another preferred embodiment, the method further comprises: performing an amplification reaction in another positive (control) reaction system or a negative (control) reaction system.
[0021] In another preferred embodiment, the positive reaction system contains genomic DNA of drug-resistant Pseudomonas putida bacteria expressing VIM.
[0022] In another preferred embodiment, the reaction system further comprises amplification elements such as DNA polymerase, single-stranded binding protein, endonuclease IV, recombinase and auxiliary protein.
[0023] In another preferred embodiment, the method further comprises the step of detecting the fluorescent signal emitted by the specific probe during or after the amplification reaction.
[0024] In another preferred embodiment, the method is enzymatic isothermal amplification (ERA).
[0025] In another preferred embodiment, the ERA reaction reagents further include: a universal solvent for the ERA reaction system, an activator, a fluorescent amplification reagent, ddH 2 One or more of O.
[0026] In another preferred embodiment, the reaction temperature of the ERA isothermal amplification is 36°C to 42°C, preferably 37°C to 39°C.
[0027] In another preferred embodiment, the reaction time of the ERA isothermal amplification is 15-60 minutes, preferably 15-20 minutes.
[0028] In a second aspect of the present invention, a non-diagnostic detection method for VIM gene is provided, the method comprising the steps of:
[0029] (a) amplifying the sample to be tested using the method described in the first aspect of the present invention; and
[0030] (b) Perform signal detection.
[0031] In another preferred embodiment, the method further comprises processing the sample to be tested to obtain genomic DNA, and then amplifying the target DNA by the method described in the first aspect of the present invention.
[0032] In another preferred embodiment, the sample to be tested is the nucleic acid of a human excrement sample.
[0033] In another preferred embodiment, the method further comprises setting up one or more control groups.
[0034] In another preferred example, the control group includes a negative control group and a positive control group.
[0035] In another preferred embodiment, the positive control group includes drug-resistant Pseudomonas putida that produces VIM.
[0036] In another preferred embodiment, the method includes qualitative detection and quantitative detection.
[0037] In another preferred embodiment, the minimum detection concentration of VIM in the method is 0.005-0.015 ng / μL.
[0038] In another preferred embodiment, the minimum detection concentration of the method is about 0.01 ng / μL.
[0039] In another preferred embodiment, the method is non-diagnostic and non-therapeutic.
[0040] In another preferred example, the detection includes fluorescence signal detection.
[0041] In another preferred embodiment, the fluorescence detection includes using a fluorescence quantitative PCR instrument or using a handheld fluorescence detector for real-time detection.
[0042] In a third aspect of the present invention, a detection kit for rapid detection of VIM gene is provided, the detection kit comprising:
[0043] A container, and the specific primer pair and probe for OXA gene in the container, wherein the specific primer pair comprises the sequence shown as SEQ ID NO:7 and the sequence shown as SEQ ID NO:9; the probe comprises the sequence shown as SEQ ID NO:1 or SEQ ID NO:11.
[0044] In another preferred embodiment, the detection kit further comprises elements such as DNA polymerase, single-strand binding protein, endonuclease IV, recombinase and auxiliary protein.
[0045] In another preferred example, the detection kit further comprises a sample processing reagent, and the sample processing reagent comprises a cell lysis solution, a nucleic acid extraction solution, a washing solution and the like.
[0046] In another preferred embodiment, the detection kit further comprises an ERA reaction reagent, wherein the ERA reaction reagent comprises a universal solvent, an activator, a fluorescent amplification reagent, ddH 2 One or more of O.
[0047] In another preferred example, the detection kit further includes a VIM positive control and a VIM negative control.
[0048] In another preferred embodiment, the detection kit further comprises an instruction manual, wherein the instruction manual is used to guide the detection of the VIM gene.
[0049] In a fourth aspect of the present invention, there is provided a use of the detection kit as described in the third aspect, for non-diagnostic and non-therapeutic detection of whether a sample to be tested contains VIM-type carbapenemase-resistant bacteria.
[0050] In another preferred embodiment, the sample to be tested is the nucleic acid of a human excrement sample.
[0051] In another preferred embodiment, the kit is used to identify whether the sample to be tested contains VIM-type carbapenemase-resistant bacteria. By detecting the VIM gene content C0 of the sample to be tested and the VIM gene content C1 in the negative control sample, if C0>C1 or C0 / C1>1.5, preferably>2, and more preferably>3, it indicates that the sample to be tested may contain VIM-type carbapenemase-resistant bacteria.
[0052] In another preferred embodiment, the kit is also used to evaluate the antibacterial effect of drugs against VIM-type carbapenemase-resistant bacteria. After the drug treatment of VIM-type carbapenemase-resistant bacteria, the VIM gene content Z0 in the sample and the VIM gene content Z1 in the sample without the drug are detected; if the ratio of Z0 / Z1 is ≤2 / 3, preferably ≤1 / 2, and more preferably ≤1 / 3, it indicates that the drug has the effect of inhibiting VIM-type carbapenemase-resistant bacteria.
[0053] In a fifth aspect of the present invention, a specific primer pair for amplifying the VIM gene is provided, the primer pair comprising a sequence as shown in SEQ ID NO:7 and a sequence as shown in SEQ ID NO:9.
[0054] In another preferred example, the primer pair includes a sequence as shown in SEQ ID NO: 8 or its complementary chain, and a sequence as shown in SEQ ID NO: 9 or its complementary chain.
[0055] In another preferred example, the primer pair includes a sequence as shown in SEQ ID NO: 3 or its complementary chain, and a sequence as shown in SEQ ID NO: 10 or its complementary chain.
[0056] In another preferred example, the primer pair includes a sequence as shown in SEQ ID NO: 7 or its complementary chain, and a sequence as shown in SEQ ID NO: 10 or its complementary chain.
[0057] In another preferred example, the primer pair includes a sequence as shown in SEQ ID NO: 8 or its complementary chain, and a sequence as shown in SEQ ID NO: 10 or its complementary chain.
[0058] In another preferred example, the primer pair includes a sequence as shown in SEQ ID NO: 12 or a complementary chain thereof, and a sequence as shown in SEQ ID NO: 19 or a complementary chain thereof.
[0059] In another preferred example, the primer pair includes a sequence as shown in SEQ ID NO: 14 or its complementary chain, and a sequence as shown in SEQ ID NO: 19 or its complementary chain.
[0060] In another preferred example, the primer pair includes a sequence as shown in SEQ ID NO: 6 or its complementary chain, and a sequence as shown in SEQ ID NO: 9 or its complementary chain.
[0061] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features specifically described below (such as embodiments) can be combined with each other to form a new or preferred technical solution. Due to space limitations, they will not be described one by one here. BRIEF DESCRIPTION OF THE DRAWINGS
[0062] Figure 1 shows the results of the ERA method for detecting the VIM gene in carbapenem-resistant Pseudomonas putida using 29 primer pairs: A. Primer pairs A1 to A8; B. Primer pairs B1 to B8; C. Primer pairs C1 to C8; D. Primer pairs D1 to D5. The primer pair information is shown in Table 2.
[0063] Figure 2 Shown are the test results of the optimal primer pair for detecting different concentrations of P. putida genomic DNA.
[0064] Figure 3 Shown are the test results of the optimal primer pair for detecting different concentrations of Pseudomonas putida genomic DNA in human feces.
[0065] Figure 4 The results of cross-reactivity specificity testing of the optimal primer pairs in different genomes are shown. DETAILED DESCRIPTION
[0066] After extensive and in-depth research and a large number of screenings, the inventors have developed a method for rapid detection of VIM genes based on enzymatic recombinant isothermal amplification (ERA). Experiments have shown that the method has a sensitivity of 0.01 ng / μL, high detection specificity, and no cross-reaction with NDM, IMP, OXA, and KPC genomic DNA, and can be used for rapid screening and detection of carbapenem-resistant bacteria producing VIM. The present invention was completed on this basis.
[0067] the term
[0068] In order to more easily understand the present invention, some technical and scientific terms are specifically defined below. Unless otherwise clearly defined in this article, all other technical and scientific terms used herein have the meanings commonly understood by those of ordinary skill in the art to which the present invention belongs. Before describing the present invention, it should be understood that the present invention is not limited to the specific methods and experimental conditions described, because such methods and conditions can be changed. It should also be understood that the terms used herein are intended only to describe specific embodiments, and are not intended to be restrictive, and the scope of the present invention will be limited only by the appended claims.
[0069] As used herein, when used in reference to a specific recited numerical value, the term "about" means that the value may vary by no more than 1% from the recited value. For example, as used herein, the expression "about 100" includes all values between 99 and 101 (e.g., 99.1, 99.2, 99.3, 99.4, etc.).
[0070] As used herein, the terms "comprise", "include", and "contain" are used interchangeably and include not only closed definitions, but also semi-closed and open definitions. In other words, the terms include "consisting of", "consisting essentially of".
[0071] Primers and probes
[0072] As used herein, the term "VIM gene specific primers" refers to primers (pairs) that amplify products having complementary strand sequences of the VIM gene. Preferred primer sequences include a primer pair consisting of SEQ ID NO:7 and SEQ ID NO:9.
[0073] In the amplification method of the present invention, in addition to the primers, the reaction system may also include one or more probes, such as a VIM fluorescent probe, for detecting the amplification effect of the VIM gene. The probe has a FAM fluorescent group and a BHQ quenching group, and has a blocking group at the 3'-end to block the polymerase extension of the probe. A preferred detection probe of the present invention has a nucleotide sequence as shown in SEQ ID NO: 1 or SEQ ID NO: 11.
[0074] In the present invention, many primer sequences were designed, and 29 primer pairs were formed by combining two of them. After a large number of experimental screenings, the combination of SEQ ID NO: 7 and SEQ ID NO: 9 with high specificity and high sensitivity was finally selected, and its sensitivity could reach 2.5277 copies / μL.
[0075] ERA
[0076] Enzymatic Recombinase Amplification (ERA) is an isothermal amplification technology developed by Suzhou Xinda Gene Technology Co., Ltd. in China. Through genetic engineering, the multi-enzyme system of recombinase, exonuclease, polymerase, etc. is modified to establish a special amplification reaction system. At room temperature, the specific segment of trace DNA / RNA can be amplified billions of times within a few minutes. It has the advantages of being fast and simple, easy to operate, and having reliable results.
[0077] The present invention uses ERA to detect VIM gene, and in addition to specific primers and probes, also includes universal reaction reagents of ERA, including one or more of universal solvent, activator, fluorescent amplification reagent, and ddH2O. When other methods are used to detect VIM, the specific primers and probes of the present invention can also be used to cooperate with reaction reagents applicable to other methods to perform VIM detection.
[0078] VIM
[0079] VIM is a common metallo-β-lactamase with strong carbapenem hydrolysis activity in clinical practice and is one of the subtypes of carbapenemases. Carbapenemases also include OXA type, NDM type, KPC type, and IMP type.
[0080] In the present invention, "carbapenem antibiotic-resistant bacteria" and "carbapenemase-resistant bacteria" are used interchangeably to refer to bacteria that express carbapenemase and are resistant to carbapenem antibiotics.
[0081] The drug-resistant strains of VIM-producing Pseudomonas putida involved in the embodiments of the present invention were donated by the First Affiliated Hospital of Nanchang University. The fecal samples of healthy volunteers were obtained from Shanghai Institute of Biomedical Technology.
[0082] The 17 primers designed for the VIM gene of the present invention include: 7 upstream primers (SEQ ID NOs: 2-8) and 2 downstream primers (SEQ ID NOs: 9-10) used in combination with the probe SEQ ID NO: 1, and 5 upstream primers (SEQ ID NOs: 12-16) and 3 downstream primers (SEQ ID NOs: 17-19) used in combination with the fluorescent probe SEQ ID NO: 11;
[0083] And two fluorescent probes (SEQ ID NO: 1 and SEQ ID NO: 11), as shown in Table 1.
[0084] Table 1 Primer and probe sequences
[0085]
[0086]
[0087] (FAM-dT)(THF)(BHQ1-dT) indicates that the probe consists of an oligonucleotide backbone consisting of a flanking FAM-dT fluorophore, a deoxynucleotide analog (tetrahydrofuran [THF] residue), and a BHQ1-dT quencher.
[0088] (C3-SPACER) here stands for: 3'-blocking group to block polymerase extension of the probe.
[0089] Detection Methods
[0090] The present invention provides a method for detecting VIM gene, comprising amplifying a sample to be tested using the specific primers of the present invention; and
[0091] During or after the amplification reaction, the amplified product of the VIM gene is detected, for example, by detecting the fluorescent signal emitted by the specific probe.
[0092] The method may also optionally include setting up one or more control groups, such as a VIM positive control group, a VIM negative control group, and the like.
[0093] Preferably, the VIM positive control group is genomic DNA of drug-resistant Pseudomonas putida bacteria expressing VIM.
[0094] Preferably, the VIM negative control group is PCR water.
[0095] In the present invention, the detection method can be a conventional PCR method, or a different method such as real-time fluorescence PCR. Preferably, the present invention uses the ERA method.
[0096] Typically, the ERA method of the present invention comprises the following steps:
[0097] S1. DNA from stool samples was extracted using thermal lysis method as a template;
[0098] S2. Amplifying DNA in an ERA reaction system comprising specific primers and specific probes of the present invention;
[0099] S3. Signal detection is performed through the fluorescent signal carried by the specific probe.
[0100] The ERA reaction system also includes other ERA reaction reagents, such as universal solvent, activator, fluorescence amplification reagent, ddH 2 O etc.
[0101] Detection Kits
[0102] The present invention also provides a VIM gene detection kit, which contains a specific detection reagent and can more accurately identify whether the sample to be tested contains carbapenemase-resistant bacteria, especially VIM-type carbapenemase-resistant bacteria. By detecting the VIM gene content C0 of the sample to be tested and the VIM gene content C1 in the negative control, if C0>C1 or C0 / C1>1.5, preferably>2, and more preferably>3, it indicates that the sample to be tested may contain VIM-type carbapenemase-resistant bacteria.
[0103] Preferably, the detection reagents of the detection kit of the present invention include specific primers, specific probes, reagents for preparing the ERA reaction system, and the like.
[0104] The detection reagent of the present invention further comprises a container and an instruction manual, wherein the container is used to contain the detection reagent, and the instruction manual is used to guide the use of the detection reagent.
[0105] Based on this kit, the present invention can further provide the antibacterial effect of the drug against VIM-type carbapenemase-resistant bacteria. After the drug treatment of VIM-type carbapenemase-resistant bacteria, the VIM gene content Z0 in the sample and the VIM gene content Z1 in the sample without the drug are detected; if the ratio of Z0 / Z1 is ≤2 / 3, preferably ≤1 / 2, and more preferably ≤1 / 3, it indicates that the drug has the effect of inhibiting VIM-type carbapenemase-resistant bacteria.
[0106] Compared with the prior art, the advantages of the present invention are as follows:
[0107] 1. The technical solution provided by the present invention uses the VIM gene as the detection target, relies on enzymatic amplification reaction, uses a specific primer and probe combination, and completes the detection within 20 minutes through constant temperature amplification technology. It does not require a complicated sample DNA pretreatment process, does not require thermal deformation of the template, is easy to operate, and takes a short time.
[0108] 2. The reaction conditions of the technical solution of the present invention are 37-42°C, and the temperature control does not need to be particularly strict, nor does it need to set multiple parameters, and the energy consumption is low. Therefore, it is particularly suitable for on-site operation.
[0109] 3. The technical solution of the present invention uses fluorescence numerical interpretation results, eliminating the process of electrophoresis verification of PCR products and avoiding aerosol contamination.
[0110] 4. The specific primer pair and probe of the VIM gene of the present invention have extremely high sensitivity, with a minimum detection concentration of about 0.01 ng / μL. They also have high specificity and have no cross-reaction with other subtype genes of carbapenemase.
[0111] 5. The VIM gene detection kit of the present invention can be used as a reagent for detecting VIM genes in clinical specimens (excreta, etc.) or clinical isolates, and can be used for scientific research and clinical applications.
[0112] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are intended to illustrate the present invention only and are not intended to limit the scope of the present invention. The experimental methods in the following examples where specific conditions are not specified are usually performed under conventional conditions, such as those described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or under conditions recommended by the manufacturer. Unless otherwise indicated, percentages and parts are weight percentages and weight parts.
[0113] Example 1. Screening for the optimal primer pair for VIM gene specific amplification
[0114] Table 2 Primer pairs for detecting specific amplification of VIM genes
[0115]
[0116]
[0117] The upstream and downstream primers described in Table 1 were paired in pairs to form 29 primer pairs, as shown in Table 2. The drug-resistant strains of Pseudomonas putida producing VIM were used as the detection objects to detect the effects of different primer pairs in the specific amplification of the VIM gene, and SEQ ID NO: 1 and SEQ ID NO: 11 were probe sequences.
[0118] DNA sample preparation: The template DNA is the genomic DNA extracted from the above strains after culture. Specifically, the strains were cultured in brain heart infusion broth (BHI) medium containing ampicillin (50 μg / mL) at 37°C according to the standard protocol, and then Plasmid DNA Mini Kit I (D6942-01) was used to extract genomic DNA according to the instructions. The template DNA was diluted 10 times in a row, and the working concentration was 10.0 ng / μl.
[0119] ERA isothermal amplification: Amplification was performed using the ERA isothermal amplification reaction system. The 50ul amplification reaction system was constructed as follows:
[0120]
[0121] The amplification temperature was 37°C and the reaction lasted for 20 min.
[0122] Fluorescence detection: During the reaction, the GS8 fluorescence thermostatic amplification instrument was used to detect the change in fluorescence value, and the fluorescence was read every 30 seconds until the reaction was completed. On the fluorescence detector, the positive group showed an "S" curve with an exponential amplification trend; the negative group showed a flat horizontal straight line with no amplification trend; the TT (time threshold) value was 4 to 8 minutes. Parallel experiments were performed with different primer pairs to detect the fluorescence results.
[0123] The test results showed that after a large number of screenings, among the 29 primer pair combinations, the following combinations were screened out: SEQ ID NO: 7 (F) + SEQ ID NO: 9 (R) and SEQ ID NO: 8 (F) + SEQ ID NO: 9 (R) with good sensitivity and specificity (Figure 1).
[0124] Example 2. Minimum detection concentration of VIM gene
[0125] Select the following optimal primer pairs and probe sequences:
[0126] SEQ ID NO:7(F):5'-GTGATGATTGCTTTTGATTGATACAGCGTGGGG-3'
[0127] SEQ ID NO:9(R):5'-CCAGCCGCCCGAAGGACATCAACGCCGCCGAC-3'
[0128] SEQ ID NO:1(probe):5'-CCCGTCTGCGAGTGTGCTCTATGGTGGTTG(FAM-dT)(THF)(BHQ1-dT)GATTTATGAGTTGTC(C3-SPACER)-3'
[0129] The genomic DNA of Pseudomonas putida expressing VIM was used as a positive template, and PCR water was used as a negative control to perform ERA isothermal amplification to detect the detection limit of ERA. In this example, the thermal lysis method was used to extract DNA. The thermal lysis method was to culture Pseudomonas putida for 5 hours (the harvested cells were approximately equivalent to 10 8 CFU / mL), resuspend 15 μL of Pseudomonas putida cells in 150 μL of extraction buffer, vortex briefly, and then incubate at 95°C for 5 minutes. Take the buffer to dilute the pure genomic DNA of Pseudomonas putida 10 times continuously to obtain a DNA sample with a concentration range of 0.01-10 ng / μL. Take 2 μL of the lysate as the template DNA in this example. The reaction system is as described in Example 1. Parallel experiments are carried out with templates of different concentrations, and the fluorescence results are detected.
[0130] The results show that the VIM gene detection method of the present invention has an extremely low detection concentration of 0.01 ng / μL (i.e. 2.5277 copies / μL). Figure 2 .
[0131] Example 3. Detection of VIM genes in human fecal samples
[0132] A 1 g stool sample was collected using a sterile spatula, thawed on ice, and added to 10 ml of ice-cold phosphate-buffered saline (PBS). 900 μL of the stool suspension was transferred to a new Eppendorf tube and inoculated with 100 μL of an overnight culture of a VIM-producing, resistant strain of Pseudomonas putida to a level of 10 8 CFU / 1.0g feces. Take 15μL of the suspension and resuspend it in 150μL of extraction buffer E, vortex gently, and boil at 95℃ for 5 minutes to release DNA. Perform 10-fold gradient dilution of the obtained sample to obtain 108 ~10 5 CFU / 1.0g of DNA sample. Take 2 μL of the lysate as the template DNA in this example. The reaction system is as described in Example 1, and the primer pairs and probe sequences are as described in Example 2. Detect the fluorescence results.
[0133] The results showed that the detection method of the present invention is effective for human fecal samples (10 5 CFU / 1.0g, corresponding to 12.5CFU Pseudomonas putida) is also effective, see Figure 3 .
[0134] Example 4. Optimal primer pairs and probe specificity for carbapenemase VIM gene
[0135] The optimal primer pair and probe sequence described in Example 2 were selected, and genomic DNA samples containing different subtypes of carbapenemase (blaNDM, blaVIM, blaIMP, blaOXA, blaKPC) at a concentration of 20 ng were used to evaluate the specificity of the primer pair and probe combination for detecting the VIM gene. The reaction system was as described in Example 1. ddH 2 O was used as a negative control to ensure that amplification would not occur in the absence of target DNA. The amplification temperature was 37°C, the reaction time was 20 min, and the fluorescence change was detected using a GS8 fluorescence thermostatic amplification instrument, with fluorescence readings every 30 s.
[0136] The results showed that the amplification curve only appeared in VIM-positive DNA samples, and there was no cross-reaction with other carbapenemase subtype genes blaNDM, blaIMP, blaOXA, and blaKPC ( Figure 4 ), indicating that the primer pair and probe for the VIM gene screened by the present invention have extremely high specificity.
[0137] All documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference individually. In addition, it should be understood that after reading the above teachings of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the claims attached to this application.
Claims
1. A non-diagnostic and non-therapeutic method for amplifying a VIM gene, characterized in that: The amplification method comprises the steps of: performing amplification in a reaction system, wherein the reaction system contains a specific primer pair for amplifying the VIM gene, and the primer pair comprises: a sequence as shown in SEQ ID NO:7, and a sequence as shown in SEQ ID NO:
9.
2. The method according to claim 1, characterized in that The method further comprises a probe comprising a sequence as shown in SEQ ID NO:1 or SEQ ID NO:
11.
3. A non-diagnostic detection method for VIM gene, characterized in that: The method comprises the steps of: (a) amplifying the sample to be tested using the method according to claim 1; and (b) Perform signal detection.
4. The method according to claim 3, characterized in that The method further comprises setting a VIM negative control and / or a VIM positive control.
5. The method according to claim 3, characterized in that The sample to be tested is a human excrement sample.
6. The method according to claim 3, characterized in that The minimum detection concentration of the method is 0.005-0.015 ng / μL.
7. A detection kit for rapid detection of VIM gene, characterized in that: The detection kit comprises: a container, and a specific primer pair and probe for the VIM gene in the container, Wherein, the primer pair includes the sequence shown as SEQ ID NO:7 and the sequence shown as SEQ ID NO:9; and the probe includes the sequence shown as SEQ ID NO:1 or SEQ ID NO:
11.
8. A use of the detection kit according to claim 7, characterized in that: Used for non-diagnostic and non-therapeutic detection of whether the test sample contains VIM type carbapenemase-resistant bacteria.
9. The use according to claim 8, characterized in that The kit is also used to evaluate the antibacterial effect of drugs against VIM-type carbapenemase-resistant bacteria.
10. A specific primer pair for amplifying the VIM gene, characterized in that: The primer pair includes the sequence shown as SEQ ID NO:7 and the sequence shown as SEQ ID NO:9.
Citation Information
Patent Citations
Detection system and kit for detecting various carbapenem drug resistance genes based on RPA-CRISPR technology
CN118086543A
Method for detecting carbapenemase-producing bacteria
WO2017187178A1
